Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Gains from Investment Securities (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Gains from Investment Securities data on record, last reported at -$14000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 102.38% year-over-year to -$14000.0; the TTM value through Dec 2025 reached $1.4 million, changed N/A, while the annual FY2025 figure was $312000.0, 56.97% down from the prior year.
  • Gains from Investment Securities reached -$14000.0 in Q4 2025 per CAI's latest filing, down from $282000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $589000.0 in Q4 2024 and bottomed at -$14000.0 in Q4 2025.